Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela Allen

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Transplantation and Cellular Therapy|January 1, 2026
ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin LymphomaSairah Ahmed, Ambuj Kumar, Paul Carpenter, et al.
Blood Advances|March 18, 2024
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapyMegan Melody, Narendranath Epperla, Geoffrey Shouse, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 studyDai Maruyama, Eric Jacobsen, Pierluigi Porcu, et al.
International Journal of Radiation Oncology, Biology, Physics|December 26, 2025
Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131Andrea C Lo, Sarah A Milgrom, Raymond Mailhot Vega, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World ExperienceMuhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
Nature Communications|September 26, 2025
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphomaAjay Subramanian, Shengqin Su, Jamie Flerlage, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Transplantation and Cellular Therapy|January 1, 2026
ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin LymphomaSairah Ahmed, Ambuj Kumar, Paul Carpenter, et al.
Blood Advances|March 18, 2024
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapyMegan Melody, Narendranath Epperla, Geoffrey Shouse, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 studyDai Maruyama, Eric Jacobsen, Pierluigi Porcu, et al.
International Journal of Radiation Oncology, Biology, Physics|December 26, 2025
Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131Andrea C Lo, Sarah A Milgrom, Raymond Mailhot Vega, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 30, 2022
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World ExperienceMuhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
Nature Communications|September 26, 2025
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphomaAjay Subramanian, Shengqin Su, Jamie Flerlage, et al.
Pageof 7